Press Release – 08.01.2018

Theraclion reports significant milestone achievement with its immunotherapy breast cancer strategy

 

First scientific communications on immunotherapy combination trial will be announced during ASCO-SITC meeting in San Francisco

 
Theraclion has been selected as unique and only medtech company at BPI Biotechnology days in Paris

 

 

Theraclion today announced that Dr. Patrick M. Dillon, MD, UVA Medical Center, Charlottesville, USA, primary investigator of the echotherapy/ immunotherapy combination trial has been accepted in the official scientific program of the ASCO (American society of clinical oncology)-STIC (Society for immunotherapy of cancer) clinical immuno-oncology symposium taking place (https://immunosym.org) on January 25th in San Francisco, USA.

Along these exciting news, Theraclion has been selected as the only medtech company to be present during the international biotechnology days in immuno oncology (Rencontres Internationales des Biotechnologies – Immuno-oncologie) 2018 at Hub BPIfrance, Paris on February 2nd 2018.

 

 

Read the press release

Print Friendly